Healthcare and Medical
Healthcare and Medical
healthcare and medical
| Market | Report Title | Report Type | Country | Published | Cost |
|
Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016 | Market Report | Global | 05/02/10 | £1,230.00 |
| Sanofi-Aventis, GlaxoSmithKline and Bristol-Myers Squibb are the leading competitors in the global Acute Coronary Syndrome market Acute Coronary Syndrome - Drug Pipeline Analysis and Market | |||||
|
Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016 | Market Report | Global | 05/02/10 | £1,230.00 |
| Bayer, Pfizer, AEterna Zentaris, Neurocrine Biosciences and KV Pharmaceuticals will be the leading competitors in the global endometriosis market Endometriosis - Drug Pipeline Analysis and Market | |||||
|
Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 | Market Report | Global | 05/02/10 | £1,230.00 |
| Stedicor is likely to dominate the future atrial fibrillation market followed by Kynapid Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 Atrial Fibrillation – Drug | |||||
|
Chronic Obstructive Pulmonary Disease (COPD) - Drug Pipeline Analysis and Market Forecasts to 2016 | Market Report | Global | 05/02/10 | £1,230.00 |
| Chronic obstructive pulmonary disease (COPD) market to be worth $7.2 billion in 2009 Chronic Obstructive Pulmonary Disease (COPD) - Drug Pipeline Analysis and Market Forecasts to 2016 Chronic | |||||
|
Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline | Market Report | Global | 01/02/10 | £2,152.00 |
| Our latest research, "Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline", which provides an insight into the global biotechnology | |||||
|
Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs | Market Report | Global | 01/02/10 | £2,152.00 |
| Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs "Biomarkers In Drug Discovery - Optimizing Drug Discovery Timeline and Costs" provides an in-depth analysis of the | |||||
|
Radio Frequency Identification (RFID) in Pharmaceuticals - Supply Chain Security Concerns Provide Impetus for RFID Adoption | Market Report | Global | 01/02/10 | £2,152.00 |
| Radio Frequency Identification products and services in the pharmaceutical industry was valued at $112m in 2008 "Radio Frequency Identification (RFID) in Pharmaceuticals - Supply Chain Security | |||||
|
Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cutting | Market Report | Global | 01/02/10 | £2,152.00 |
| A leading business intelligence provider, has released its latest report, "Drug Discovery in India and China - Gaining Momentum with Increasing Pressure on Cost Cutting." It provides key data, | |||||
|
Pharmaceutical Pricing and Reimbursement - Reference Pricing and Economic Evaluations Will Dominate Future Pricing and Reimbursement Strategies | Market Report | Global | 01/02/10 | £2,152.00 |
| A leading business intelligence provider, has released its latest research, "Pharmaceutical Pricing and Reimbursement - Reference Pricing and Economic Evaluations Will Dominate Future Pricing and | |||||
|
Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma | Market Report | Global | 01/02/10 | £2,152.00 |
| A leading business intelligence provider, has released its latest research "Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma", which provides insights into the | |||||
|
Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotechnology Clusters, Funding Characteristics and Regulatory Landscape | Market Report | Global | 01/02/10 | £2,152.00 |
| A leading business intelligence provider, has released its latest research, "Small and Medium Biopharmaceutical Enterprises in North America and Europe - Biotech Clusters, Funding Characteristics and | |||||
|
Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential | Market Report | Global | 01/02/10 | £2,152.00 |
| A leading business intelligence provider, has released its latest research, "Big Pharma's Key Lifecycle Management Strategies: Maximizing the Market Potential." It provides key data, information and | |||||
|
Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis | Market Report | Global | 01/02/10 | £2,152.00 |
| A leading business intelligence provider, has released its latest research "Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis". It is an essential source of information and | |||||
|
Outsourcing in the Global Medical Equipment Industry - The Market Expected to Register High Growth in the Future | Market Report | Global | 29/01/10 | £2,152.00 |
| Contract manufacturing accounted for 90% of the global medical equipment outsourcing market in 2009 Outsourcing in the Global Medical Equipment Industry - The Market Expected to Register High Growth | |||||
|
Global Nuclear Feed Water Market Analysis and Forecasts to 2020 | Market Report | Global | 29/01/10 | £2,152.00 |
| Alstom Power, Foster Wheeler, Holtec International and Mitsubishi Heavy Industries set to benefit from growth in the nuclear feed water heater market Global Nuclear Feed Water Market Analysis and | |||||
|
Global Cardiovascular Devices Pipeline Landscape: Analysis of Key Upcoming Products and Technologies | Market Report | Global | 29/01/10 | £1,230.00 |
| Global cardiovascular devices market is forecast to reach $54.9 billion in 2016 Global Cardiovascular Devices Pipeline Landscape: Analysis of Key Upcoming Products and Technologies While the | |||||
|
InSight Health Services Holdings Corp. - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| nSight Health Reports Revenues Of $50.1 Million In Q1 Fiscal 2010 InSight Health Services Holdings Corp. - Financial Analysis Review;InSight Health Services Holdings Corp (InSight Health Services) | |||||
|
Allion Healthcare, Inc. - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| HIG Capital To Acquire Allion Healthcare Allion Healthcare, Inc. - Financial Analysis Review;Allion Healthcare, Inc. (Allion) is one of US’s leading providers of specialty pharmacy and disease | |||||
|
Kobayashi Pharmaceutical Co Ltd - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| Kobayashi Pharmaceutical Posts Net Sales Of JPY125.6 Billion For Fiscal 2009 Kobayashi Pharmaceutical Co Ltd - Financial Analysis Review;Kobayashi Pharmaceutical Co Ltd (Kobayashi Pharmaceutical) is | |||||
|
Zydus Cadila Healthcare Limited - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| Zydus Cadila To Initiate Clinical Trials Of H1N1 Vaccine Zydus Cadila Healthcare Limited - Financial Analysis Review;Zydus Cadila Healthcare Limited (Zydus Cadila) is engaged in discovery, | |||||
|
Zentiva NV - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| Zentiva Plans To Manufacture Generic Version Of Viagra Zentiva NV - Financial Analysis Review;Zentiva NV is a leading pharmaceutical company in Czech Republic, Turkey, Romania, Poland, Slovakia and | |||||
|
YaSheng Group Ltd. - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| YaSheng Group Ltd. - Financial Analysis Review;YaSheng Group Ltd. is a US based holding company, engaged in agricultural operations in China. The company is one of the leading agricultural companies | |||||
|
Wockhardt Limited - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| Wockhardt Limited - Financial Analysis Review;Wockhardt Limited is subsidiary of Khorakwala Holdings and Investments Private Limited. The company is an Indian research and technology oriented | |||||
|
WellCare Health Plans, Inc - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| WellCare Resolves SEC Probe WellCare Health Plans, Inc - Financial Analysis Review;WellCare Health Plans, Inc. (WellCare) is a leading provider of managed care services to government-sponsored | |||||
|
USANA Health Sciences - Financial Analysis Review | Company Profile | 28/01/10 | £77.00 | |
| Usana Unveils Seasonal Vitamin D Supplement USANA Health Sciences - Financial Analysis Review;USANA Health Sciences, Inc. (USANA) is engaged in developing, manufacturing and distributing high-quality | |||||
